Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century

Author:

Pulte Dianne12,Gondos Adam1,Brenner Hermann1

Affiliation:

1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; and

2. University of Medicine and Dentistry of New Jersey (UMDNJ)–New Jersey Medical School/University Hospital Cancer Center, Newark

Abstract

Abstract Acute lymphoblastic leukemia (ALL) is an uncommon but highly fatal disease in adults. We used period analysis to data from the Surveillance, Epidemiology, and End Results (SEER) database to disclose changes in outcomes for patients diagnosed with ALL in the United States in the 2 decades between 1980–1984 and 2000–2004. Major improvement in survival was observed for patients less than 60 years of age. Improvement in survival was greater for women than for men, but was significant for both genders. The greatest improvement was seen in patients aged 15 to 19, in whom 5-year relative survival improved from 41.0% to 61.1%, and 10-year survival improved from 33.0% to 60.4%. Lesser but significant improvements were seen for age groups 20–29, 30–44, and 45–59. Survival for patients aged 60 and over remained essentially unchanged at levels around or below 10%, respectively. Survival has improved for patients with ALL over the time period studied, but treatment of older patients remains a difficult issue.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference27 articles.

1. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program Accessed June 20, 2008 http://www.seer.cancer.gov/statfacts/html/alyl.html

2. Treatment of adult acute lymphoblastic leukemia.;Goekbuget;Hematology (Am Soc Hematol Educ Program)

3. An alternative approach to monitoring cancer patient survival.;Brenner;Cancer,1996

4. Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications.;Brenner;Eur J Cancer,2004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3